ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0258

Understanding Monogenic Behçet’s Disease Pathophysiology: Impact of Pathogenic Variant L227X Associated with Autoinflammatory A20 Haploinsufficiency on Cellular Survival and Proliferation

Patricia Aires1, Daniela Pioto1, Maria Teresa TErreri2 and Sandro Perazzio3, 1Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, 2UNIFESP, São Paulo, Brazil, 3Universidade de Sao Paulo (Unifesp); Universidade de São Paulo (USP); Fleury Laboratories, São Paulo, Brazil

Meeting: ACR Convergence 2023

Keywords: Autoinflammatory diseases, Behçet's Syndrome, Cell Death, genetics, immunology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: A20, encoded by TNFAIP3, plays a critical role in NF-κB pathway regulation. A20 haploinsufficiency is a monogenic disorder form of Behçet’s disease with a wide spectrum of phenotypic manifestations. This study aimed to establish an in vitro model to investigate the impact of the TNFAIP3 L227X pathogenic variant on cellular survival and proliferation.

Methods: Jurkat (T cell neoplastic lineage) and THP-1 (monocytic lineage) cells were transfected with a plasmid engineered to express either wild-type (WT) or L227X TNFAIP3. A20 protein expression was assessed, and Ki-67 expression was utilized as a measure of cell proliferation. Cell resistance to apoptosis was evaluated using annexin V and propidium iodide staining (before and after ultraviolet [UV] radiation or anti-CD95 stimulus). Jurkat and THP-1 cells were specifically stimulated with IL-2 + phytohemagglutinin (PHA) and phorbol-miristate-acetate (PMA), respectively. Non-transfected (NT) cells and empty plasmid (EP)-transfected cells served as controls. Flow cytometry was employed for all analyses.

Results: TNFAIP3-L227X transfection reduced A20 protein expression in both THP-1 (MFI=581.0 ± 329.0) and Jurkat cells (763.7 ± 17.32) compared to NT cells (respectively, 1169 ± 51.50 [p < 0.01] and 694.5 ± 0.5 [p < 0.05], figure 1). THP-1-TNFAIP3-L227X exhibited increased Ki-67 expression after PMA stimulus (19180 ± 4473), in contrast to THP-1-NT cells (2435 ± 187.4, p< 0.001, figure 2A). Moreover, THP-1-TNFAIP3-L227X cells displayed significantly higher resistance to apoptosis at baseline and when stimulated with anti-CD95 (with or without PMA) or exposed to UV radiation (figure 2B). Jurkat-TNFAIP3-L227X (19960 ± 1048) showed elevated Ki-67 levels at baseline compared to Jurkat-NT cells (13520 ± 249.5, p< 0.05), but not compared to Jurkat-EP cells (31870 ± 2843, figure 3A), which exhibited a substantial baseline increase in Ki-67 expression. Intriguingly, TNFAIP3-WT transfection produced opposite effects, including lower proliferation rates and reduced resistance to apoptosis in both THP-1 (figure 2B) and Jurkat cells (figure 3B).

Conclusion: TNFAIP3 L227X variant significantly impacts cell survival and proliferation in monocytic and T-lymphoid cell lineages, promoting a predominantly hyperproliferative state. Reduced A20 protein expression in both Jurkat and THP-1 suggests that L227X variant may exert a dominant negative effect on the WT TNFAIP3 gene. Despite the limitations inherent to this cell model, our results suggest the potential utility of these functional assays for diagnosing patients suspected of harboring TNFAIP3 genetic variants.

Supporting image 1

Figure 1: A20 protein expression in THP_1 (A) and Jurkat (B) cells transfected with L227X TNFAIP3 (green), compared to non-transfected cells (red) and cells transfected with WT TNFAIP3 (blue) or empty plasmid (grey). * p < 0.05; ** p < 0.01; *** p < 0.001.

Supporting image 2

Figure 2: Proliferation rates, determined by Ki-67 expression levels (A) and resistance to apoptosis, determined by percentage of viable cells (B), in THP_1 cells transfected with L227X TNFAIP3 (green), compared to non-transfected cells (red) and cells transfected with WT TNFAIP3 (blue) or empty plasmid (grey). NS = non-stimulated. PMA = phorbol-miristate-acetate. UV = ultraviolet radiation. * p < 0.05; ** p < 0.01; *** p < 0.001.

Supporting image 3

Figure 3: Proliferation rates, determined by Ki-67 expression levels (A) and resistance to apoptosis, determined by percentage of viable cells (B), in Jurkat cells transfected with L227X TNFAIP3 (green), compared to non-transfected cells (red) and cells transfected with WT TNFAIP3 (blue) or empty plasmid (grey). NS = non-stimulated. IL_2 = human interleukin_2. PHA = phytohemagglutinin. UV = ultraviolet radiation. * p < 0.05; ** p < 0.01; *** p < 0.001.


Disclosures: P. Aires: None; D. Pioto: None; M. TErreri: None; S. Perazzio: None.

To cite this abstract in AMA style:

Aires P, Pioto D, TErreri M, Perazzio S. Understanding Monogenic Behçet’s Disease Pathophysiology: Impact of Pathogenic Variant L227X Associated with Autoinflammatory A20 Haploinsufficiency on Cellular Survival and Proliferation [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/understanding-monogenic-behcets-disease-pathophysiology-impact-of-pathogenic-variant-l227x-associated-with-autoinflammatory-a20-haploinsufficiency-on-cellular-survival-and-proliferation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/understanding-monogenic-behcets-disease-pathophysiology-impact-of-pathogenic-variant-l227x-associated-with-autoinflammatory-a20-haploinsufficiency-on-cellular-survival-and-proliferation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology